摘要:
This invention relates to certain sulfonamide derivatives that are inhibitors of procollagen C-proteinase, pharmaceutical compositions containing them, methods for their use and methods for preparing these compounds.
摘要:
This invention relates to certain sulfonamide derivatives that are inhibitors of procollagen C-proteinase, pharmaceutical compositions containing them, methods for their use and methods for preparing these compounds.
摘要:
A compound of the Formula (I): wherein Z, R1, R, and Ar2 are as defined in the specification. This invention also relates to sulfonamide compounds of the Formula (I) that are inhibitors of procollagen C-proteinase, pharmaceutical compositions containing them, methods for their use, and methods for preparing the compounds.
摘要:
In various aspects, the present invention relates to non-peptidic compounds, which modulate calcitonin and amylin receptor activity; to processes for the preparation of some such compounds; and to pharmaceutical compositions including such compounds. Compounds of the invention are useful as calcitonin and/or amylin agonists and in the treatment of bone diseases and metabolic diseases.
摘要:
In various aspects, the present invention relates to novel compounds, which modulate calcitonin and amylin receptor activity; to processes for the preparation of such compounds; and to pharmaceutical compositions including such compounds. Compounds of the invention are useful as calcitonin and/or amylin agonists and in the treatment of bone disease such as osteoporosis, Paget's disease, hypercalcemia, and in the treatment of metabolic diseases, such as insulin-requiring states.
摘要:
The present invention provides low molecular weight compounds useful as cytokine inhibitors, and compositions thereof. In particular, compounds of the invention are useful as anti-inflammatory agents. There are further provided methods for the preparation of such agents and their use in preventing or treating conditions mediated by cytokines such as arthritis.
摘要:
The present invention describes cyclic peptide compounds which modulate integrin mediated adhesion. These compounds can inhibit both .beta..sub.1 and .beta..sub.2 mediated adhesion. The invention further relates to therapeutic uses for these compounds in the treatment of adhesion related pathologies.